Therapeutic Dose of Apixaban (Eliquis) for Axillary Vein DVT
For acute axillary vein deep vein thrombosis, treat with apixaban 10 mg orally twice daily for the first 7 days, then reduce to 5 mg orally twice daily for the remainder of the initial treatment period (minimum 3 months). 1, 2
Initial Treatment Phase (First 7 Days)
The FDA-approved dosing for DVT treatment begins with a loading phase:
- Apixaban 10 mg orally twice daily for 7 days 2
This higher initial dose rapidly achieves therapeutic anticoagulation without requiring parenteral bridging therapy (unlike dabigatran or edoxaban). This represents a significant practical advantage, as you can start oral therapy immediately without heparin overlap 1.
Maintenance Treatment Phase (Day 8 onwards)
After completing the 7-day loading phase:
The 2021 ACC Expert Consensus and 2020 ASH Guidelines consistently recommend this dosing regimen for all venous thromboembolism, including upper extremity DVT 1, 3. Axillary vein thrombosis is treated identically to lower extremity DVT—there is no separate dosing protocol for upper extremity location 4.
Extended/Secondary Prevention (After 6 Months)
If the patient requires extended anticoagulation beyond 6 months due to:
- Unprovoked DVT
- Persistent risk factors (active cancer, thrombophilia)
- Lack of vein recanalization
Consider reducing to apixaban 2.5 mg orally twice daily 1, 3, 5
The 2021 CHEST Guidelines and ACC Consensus support this reduced-dose strategy for secondary prevention after completing initial treatment 5. Recent evidence from the API-CAT trial (2025) demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose for preventing recurrent VTE while significantly reducing bleeding complications 6. A 2023 observational study specifically in upper extremity DVT showed no recurrent thrombotic events with low-dose DOAC continuation 4.
Important Dosing Considerations
Renal function adjustments: Unlike atrial fibrillation dosing, there are no routine dose reductions for renal impairment in VTE treatment with apixaban 2. The standard VTE dosing applies even with moderate renal dysfunction.
Drug interactions: If the patient is taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), reduce the dose by 50% during the maintenance phase 2. This means 2.5 mg twice daily instead of 5 mg twice daily after day 7.
Cancer-associated thrombosis: Use the same dosing regimen. DOACs are now preferred over LMWH for cancer-associated VTE due to superior compliance and comparable efficacy 1, 6. However, monitor closely in patients with GI or genitourinary malignancies due to higher bleeding risk 1.
Duration of Treatment Algorithm
Provoked by major transient risk factor (surgery, trauma): Treat for 3 months, then stop 5
Provoked by minor transient risk factor or persistent risk factor (central line, active cancer, thrombophilia): Treat for minimum 3-6 months, then reassess for extended therapy 5
Unprovoked DVT: Treat for 3-6 months, then strongly consider extended anticoagulation with reduced-dose apixaban 2.5 mg twice daily 3, 5
Reassess annually if continuing extended anticoagulation 5
Common Pitfalls to Avoid
- Do not use atrial fibrillation dosing (5 mg twice daily from the start)—this skips the critical 10 mg loading phase needed for acute VTE 1
- Do not reduce dose for renal impairment during VTE treatment unless also taking strong drug interaction medications 2
- Do not bridge with heparin—apixaban can be started immediately as monotherapy 1, 2
- Do not assume upper extremity DVT needs different dosing—treat identically to lower extremity DVT 4